CLODERM (clocortolone pivalate) by Enterprise Therapeutics is clinical pharmacology topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1977.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
CLODERM (clocortolone pivalate) is a topical corticosteroid cream approved in 1977 for the treatment of inflammatory and pruritic dermatoses. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms, with efficacy correlating to vasoconstrictor potency. The drug is absorbed through intact skin and metabolized hepatically before renal excretion.
Product is approaching loss of exclusivity with minimal Part D activity (75 claims, $31K annual spend), indicating a mature, declining market presence with limited commercial team expansion.
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CLODERM at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CLODERM offers limited career growth due to its LOE-approaching status and minimal market presence (75 annual claims, $31K spending). This role is best suited for professionals focused on legacy portfolio management, compliance, and cost containment rather than commercial expansion or innovation.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo